Coverage and Access Issues Affecting Women Living with Autoimmune Diseases
February 7 @ 12:00 pm - 1:00 pm EST
The rate of autoimmune diseases and conditions in the United States is rising—and women are disproportionately affected.
Generally, autoimmune diseases cannot be cured, so treatment focuses on managing symptoms and slowing the progression and impacts of the disease. However, utilization management (UM) tools, such as prior authorization and step therapy, are increasingly being used by payers and can cause delays in care, which can be devastating for patients, resulting in disease progression and higher costs over time.
In this webinar, panelists will review coverage and access issues that could negatively affect those with autoimmune diseases and conditions, the tenants of prior authorization and step therapy, discuss the role these policies can play in patient outcomes and on providers, and how current policies could be modified to better serve individuals living with autoimmune diseases and conditions.
While this webinar is open to the public, SWHR encourages new members of the 118th Congress and their staff to attend. *This event is widely attended and relevant to official duties.
This event is free and open to the public.
Check out the full SWHR 2023 Autoimmune Policy series:
- The Growing National Burden of Autoimmune Diseases and the Role of Policy in Improving Outcomes (January 17, 2023)
- Coverage and Access Issues Affecting Women Living with Autoimmune Diseases (February 7, 2023)
- Diversity in Autoimmune Clinical Trials: Addressing Areas of Need and Opportunity (Spring 2023)
- The Role of Federal Agencies in Supporting Women with Autoimmune Diseases and Conditions (Spring 2023)
Anna Hyde, MA
Anna Hyde, MA, is the Vice President of Advocacy and Access at the Arthritis Foundation. She oversees both the federal and state legislative programs, in addition to grassroots engagement. Her focus is to raise the visibility of arthritis as a public health priority, build support for federal and state legislation that ensures access to affordable, high-quality health care, and enhance patient engagement in the policy-making process. Anna previously served as Senior Director of Advocacy and Access, managing the federal affairs portfolio and overseeing the state advocacy team.
Prior to joining the Arthritis Foundation in 2014, Anna worked as Senior Manager for Federal Affairs at the American Congress of Obstetricians and Gynecologists, where she managed a portfolio of issues including appropriations, physician workforce, and health IT. She began her health policy career as a Congressional Fellow for Energy and Commerce Committee members, where she drafted legislation and staffed Committee activities. Anna received a BA in History from Southern Methodist University, and taught junior high and high school history before moving to Washington D.C. in 2007 to pursue an MA in Political Science from American University.
Sarah Buchanan is responsible for identifying and pursuing federal issues of significance to individuals with psoriatic disease; developing policies and resources to advocate on these issues; and representing the National Psoriasis Foundation (NPF) in federally focused coalitions and before federal policymakers. In addition to advocating directly to federal policymakers within Congress and the federal agencies, she will also advocate directly with the private insurance sector and other allied stakeholders to improve policies and advance the health and wellness of the psoriatic disease community.
Sarah is a 12-year health policy veteran with a passion for collaborating with patients, families, and providers on public policies to improve patient access to care. Prior to joining the NPF, Sarah established an impactful advocacy program at the Crohn’s & Colitis Foundation, including leadership in state and federal coalitions. She has also served as an appropriations lobbyist with a focus on medical research programs at the Health and Medicine Counsel.
Policymaker Event, SWHR Event, Webinar
SWHR’s Autoimmune Policy Program is supported by an educational sponsorship from Horizon Therapeutics. SWHR maintains independence and editorial control over program development, content, and work products.